Non-Alcoholic Fatty Liver Disease
Conditions
Interventions
35 subjects diagnosed with Non-Alcoholic Fatty Liver Disease will receive soluble coffee corresponding to 3 cups per day for 6 months. Laboratory data, fecal samples and liver elastography will be col
Dietary supplement
Sponsors
Instituto de Nutrição Josué de castro
Hospital Universitário Clementino Fraga Filho
Eligibility
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with non-alcoholic fatty liver disease through Fibroscam; both genders; aged between 18 and 65 years.
Exclusion criteria
Exclusion criteria: Patients with: another cause of hepatic steatosis (alcohol, virus, genetics) or advanced liver disease; chronic kidney disease thyroid diseases; cushing's syndrome; cancer; pregnant or lactating women; history of upper gastrointestinal surgery; use of medications for weight loss; report of sensitivity to coffee; consumption of more than 3 cups of coffee per day.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic impairment, serum alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (AF) and gamma glutamyl transpeptidase (GGT) levels are expected to be decreased, based on the finding of a variation of at least 5% in pre and post-intervention measurements.;It is expected that the liver's degree of stiffness will be reduced by examining the hepatic elastography, based on a variation of at least 1 level in the pre- and post-intervention measurements. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the behavior of the clinical indicators related to the glycidic profile, verified through serum glucose and fasting insulin levels and HOMA-ir calculation.;To evaluate the behavior of the clinical indicators related to the lipid profile, verified by serum levels of total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides (TG).;To evaluate the behavior of oxidative stress markers, verified by oxidative damage of lipoperoxidation (TBARS), antioxidant defenses (SOD, GPx) and total antioxidant potential of plasma (TRAP).;Evaluate the behavior of inflammation markers, verified through serum levels of interleukin-6 (IL-6).;To evaluate the behavior of the anthropometric parameters, verified through BMI and values of waist, abdominal, hip and neck circumference, and body fat percentage.;An increase in the beneficial bacterial population is expected, measured through the analysis of the intestinal microbiota profile present in the feces.;Genetic differences are expected in the clinical evolution of the disease, verified through the presence or not of the polymorphism in the PNPLA3 gene. | — |
Countries
Brazil
Contacts
Public ContactWilza Peres
Universidade Federal do Rio de Janeiro
Outcome results
None listed